Salubris(SZ:002294)2022-12-08 06:46Group 1: Product Performance - Clopidogrel is primarily used in PCI procedures, with significant applications in therapeutic prevention and neurology [1] - The product "Taijia" has maintained stable growth this year, although the growth rate has slightly slowed due to a high base [2] - The sales of "Xinglitai" are currently focused on bidding and academic promotion, with lower sales expected this year due to its recent launch [2] Group 2: Market and Regulatory Environment - The national bidding situation emphasizes quality and follows government guidelines, encouraging domestic manufacturers to reach international standards [2] - The company’s overall bidding success remains good, with specific details available on the drug bidding website [2] Group 3: Research and Development - The patent for "Xinglitai" protects both the compound and the synthesis method, expiring in 2026 [3] - The company is exploring opportunities in the medical services sector, supported by government policies, but emphasizes the need for detailed feasibility studies before proceeding [3] - The stent project has completed multi-center randomized controlled clinical trials, with production application expected after the clinical report is finalized by the end of this year [3] Group 4: Future Product Pipeline - The company has multiple products in development, focusing on high-end prescription drugs and biomedicine, although it is difficult to identify which will be blockbuster products [4]